Entasis Therapeutics Holdings Inc. (ETTX) financial statements (2021 and earlier)

Company profile

Business Address 35 GATEHOUSE DRIVE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:534185
Cash and cash equivalents531649
Short-term investments 2536
Other undisclosed cash, cash equivalents, and short-term investments 00
Receivables212
Prepaid expense45 
Other current assets12 
Other undisclosed current assets (0)2
Total current assets:604989
Noncurrent Assets
Operating lease, right-of-use asset12
Property, plant and equipment000
Other noncurrent assets000
Total noncurrent assets:120
TOTAL ASSETS:625189
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities454
Accounts payable111
Accrued liabilities111
Employee-related liabilities322
Debt 1 
Other undisclosed current liabilities422
Total current liabilities:986
Noncurrent Liabilities
Long-term debt and lease obligation11 
Operating lease, liability11
Liabilities, other than long-term debt  0
Deferred rent credit  0
Other undisclosed noncurrent liabilities(1)  
Total noncurrent liabilities:110
Total liabilities:996
Stockholders' equity
Stockholders' equity attributable to parent524283
Common stock000
Additional paid in capital237176173
Accumulated other comprehensive loss  (0)
Accumulated deficit(184)(134)(90)
Total stockholders' equity:524283
TOTAL LIABILITIES AND EQUITY:625189

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit: 75
Operating expenses(54)(54)(43)
Operating loss:(54)(47)(38)
Other undisclosed income from continuing operations before equity method investments, income taxes446
Loss from continuing operations before income taxes:(50)(43)(32)
Income tax expense (1)(0)
Net loss attributable to parent:(50)(44)(33)
Undistributed earnings (loss) allocated to participating securities, basic  (9)
Net loss available to common stockholders, diluted:(50)(44)(42)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(50)(44)(33)
Comprehensive loss:(50)(44)(33)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 0(0)
Comprehensive loss, net of tax, attributable to parent:(50)(44)(33)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: